WuXi AppTec Co Ltd

Two biopharmaceutical CRO companies on the STAR Market, Medicilon and Innostar, have released their 2026 half-year reports, both swinging to profitability. Medicilon reported first-half revenue of 761 million yuan, up 40.91 percent year on year, with net profit attributable to shareholders of 51.6 million yuan, compared with a loss of 12.9 million yuan in the same period last year. Innostar reported first-half revenue of 465 million yuan, up 23.92 percent year on year, with net profit attributable to shareholders of 39.17 million yuan, compared with a loss of 15.19 million yuan a year earlier. Both companies said the improvement was driven by a recovery in global innovative drug R&D demand, ample order backlogs, and higher capacity utilization. CRO leader WuXi AppTec previously disclosed in its half-year report that first-half revenue reached 28.9 billion yuan, up 38.93 percent year on year, with net profit attributable to shareholders of 11.08 billion yuan, up 29.43 percent, and raised its full-year revenue guidance to between 58.5 billion and 60.5 billion yuan.

On August 13, China's A-share pharmaceutical sector strengthened, with Boji Medical and Longshen Rongfa up by the 20 percent daily limit, Fangsheng Pharmaceutical and Jiuzhou Pharmaceutical up by the 10 percent daily limit, and innovative drug companies such as Yahong Meditech, Junshi Biosciences, Dizal Pharmaceutical, and Zhongsheng Pharmaceutical rising more than 3 percent. Since WuXi AppTec released its better-than-expected 2026 interim report on August 3, the pharmaceutical sector has kept climbing, with Wanbang Pharmaceutical posting three boards in two days, Yatai Group three consecutive daily limits, and Yuyuan Pharmaceutical four boards in five days. Southwest Securities research argues that WuXi AppTec's interim net profit attributable to the parent exceeded 10 billion yuan for the first time and raised its guidance, while BeiGene, RemeGen, and Innovent Biologics released positive results at the same time, creating a sector-wide resonance effect. WuXi AppTec's first-half revenue was 28.9 billion yuan, up 38.93 percent year on year, with net profit attributable to the parent of 11.08 billion yuan, up 29.43 percent. BeiGene's first-half total revenue was 22.22 billion yuan, up 26.8 percent year on year, with net profit attributable to the parent of 3.271 billion yuan, up 627.1 percent, and it raised its full-year revenue guidance to between 44.9 billion and 46.2 billion yuan. Innovent Biologics' first-half product revenue exceeded 8.2 billion yuan, up more than 55 percent year on year. In addition, Akeso's ivonescimab injection combined with chemotherapy was approved for first-line treatment of advanced squamous non-small cell lung cancer, marking the drug's third indication in lung cancer. On August 10, China's pharmaceutical industry announced three deals, including a collaboration between BeiGene and Revolution Medicines, a partnership between Innovent Biologics and Daiichi Sankyo, and a collaboration between Gan & Lee Pharmaceuticals and Menarini, with a potential total transaction value of 726 million euros. On August 12, CSPC Pharmaceutical Group received a 30 million US dollar upfront payment from AstraZeneca. Xiangcai Securities research argues that this round of the pharmaceutical sector's rally will be significantly more durable than previous ones, based on three judgments: the pharmaceutical sector absorbing capital outflows from the technology sector, improving interim results from CXO companies, and the initial emergence of Chinese pharmaceutical companies' global expansion.

Construction Machinery has received notice from its controlling shareholder, Shaanxi Coal Group, approving the plan to acquire 100% equity in Pucheng Clean Energy Chemical Company through a combination of share issuance and cash payment, along with a concurrent fundraising. Trading in the company's shares will be halted from market open on August 11, with the halt expected to last no more than 10 trading days. Jiangbolong reported first-half revenue of 24.088 billion yuan, up 136.26% year-on-year, and net profit attributable to the parent of 10.577 billion yuan, up 71,528.66%. It also plans to repurchase shares worth 400 million to 800 million yuan for equity incentives or employee stock ownership plans, with a repurchase price not exceeding 735 yuan per share. Heduan Intelligent saw a net institutional seat purchase of 50.8161 million yuan on August 10, accounting for 1.91% of total turnover. In addition, WuXi AppTec posted first-half net profit attributable to the parent of 11.08 billion yuan, up 29.43% year-on-year, and significantly raised its full-year performance guidance, with its share price continuing to climb. Gan & Lee Pharmaceuticals reached an exclusive licensing agreement with Menarini, granting it the rights to register and commercialize Bofanglutide for overweight or obesity indications in 39 European countries and regions, with milestone payments of up to 664 million euros.

Innovative drug concept stock Baihua Pharmaceutical achieved its 5th consecutive daily limit, Harbin Pharmaceutical Group hit its 2nd consecutive daily limit, and Bio-Techne surged over 18%. In related news, WuXi AppTec announced that a U.S. court has ruled on its preliminary injunction motion, shielding the company from immediate adverse effects of the 1260H designation during the judicial process challenging that designation. The company had previously filed a lawsuit over the U.S. Department of Defense's decision to place it on the 1260H list.

WuXi AppTec has successfully obtained a temporary injunction from a US court, suspending the US Department of Defense's restrictions that placed the company on the 1260H list of entities linked to the Chinese military. The ruling shields the company from immediate adverse effects while it challenges the designation through judicial proceedings. Market analysts believe that if the company is subsequently removed from the list, it would support a valuation recovery for WuXi AppTec and the broader CXO sector. The company's previously released half-year report for 2026 showed that revenue from continuing operations rose 48 percent year on year, adjusted non-IFRS net profit surged 83.2 percent, and its order backlog reached 66.43 billion yuan, prompting a significant upward revision of its full-year guidance. Boosted by these developments, as of August 7, the GF Hong Kong Innovative Drug ETF, in which WuXi AppTec has a weighting of over 8 percent, has rebounded 28.27 percent from its year low on June 10, and the GF Innovative Drug ETF gained 7.77 percent over the past week.

WuXi AppTec's first-half 2026 results significantly beat market expectations, sparking a broad rally in innovative drug concept stocks. Huaxi Securities noted that the company achieved adjusted profit of 11.57 billion yuan in the first half, up 83.2 percent year-on-year. Second-quarter revenue reached 16.46 billion yuan, with continuing operations growing 55.2 percent year-on-year. Adjusted profit was 6.97 billion yuan, up 92 percent, and net margin hit 42.4 percent. The company has fully raised its full-year revenue guidance. As of the end of June, backlog for continuing operations grew 23.6 percent year-on-year. The D&M pipeline added 699 new molecules in the first half, including 155 conversions from R to D, up 70 percent year-on-year. The full-year growth forecast for the TIDES business has been raised to around 45 percent. On the market, Baihua Pharmaceutical hit its fifth consecutive daily limit up, Harbin Pharmaceutical Group and Harbin Sanlian both reached their second straight daily limit up, Biocytogen and Pharmaron rose by the 20 percent daily limit, while WuXi AppTec and HitGen also advanced.

The CRO concept surged again in early trading today, with Novoprotein hitting the 20% daily limit up shortly after the open, following a limit-up close in the previous session. Hepalink and Baihua Pharmaceutical also reached their daily limit up, while Medicilon, HitGen, and Sino Biological rose over 7%. In news, CRO leader WuXi AppTec disclosed on Sunday evening that the U.S. District Court for the District of Columbia ruled on its motion for a preliminary injunction, shielding the company from immediate adverse effects of the 1260H designation during the judicial challenge. WuXi AppTec also released its half-year report on August 3, showing attributable net profit of 11.08 billion yuan in the first half of 2026, up 29.43% year-on-year, and raised its full-year 2026 guidance, with continuing operations revenue growth now expected at 35% to 39%, up from the previous 18% to 22%. Meanwhile, the aquaculture sector rebounded sharply, with Yisheng Livestock hitting the daily limit up within eight minutes of trading, Xiaoming Agriculture rising over 6%, and Minhe Animal Husbandry, Shennong Group, and Xiantan rising over 5%. The Dalian Commodity Exchange's live hog main contract LH2611 has rebounded over 4% cumulatively over the past five trading days. A Cinda Futures research note pointed out that the national breeding sow herd stood at 37.8 million head at the end of June 2026, a cumulative reduction of 7.35% from the earlier peak, while sample enterprise piglet births have declined for three consecutive months, strengthening expectations of far-month capacity reduction.

WuXi AppTec has achieved a phased progress in its lawsuit against the U.S. Department of Defense over the 1260H designation. The U.S. District Court for the District of Columbia granted the company's motion for a preliminary injunction, barring the Department of Defense from enforcing the designation during the judicial process. The designation was made on June 8 this year, placing WuXi AppTec on the list of Chinese military companies. The company filed a lawsuit on June 11 and subsequently submitted a motion for a preliminary injunction. WuXi AppTec welcomed the court's ruling and stated that all its businesses continue to operate normally. This preliminary injunction is not a final judgment, and the subsequent judicial process will continue to advance.

Talkweb Information System released its 2026 semi-annual report, achieving operating revenue of 1.312 billion yuan, up 0.39% year-on-year, with net profit attributable to shareholders of the listed company at 69.222 million yuan, down 12.16% year-on-year. The company plans to distribute a cash dividend of 0.25 yuan for every 10 shares to all shareholders. As of the end of the reporting period, the company had over 30 products certified through OpenHarmony compatibility assessment, with related products in the market expansion and application stage. In other news, WuXi AppTec announced that a U.S. court has granted its preliminary injunction motion, shielding the company from immediate adverse impact while it challenges the U.S. Department of Defense's 1260H designation in judicial proceedings. Gaozheng Explosives' controlling shareholder is set to change to Tibet Geology and Mineral Resources Group. Ningxia Building Materials plans to repurchase shares worth 100 million to 200 million yuan for cancellation. Wuhan P&S Information Technology saw semi-annual net profit surge 209.5% year-on-year. Galaxy Microelectronics' semi-annual net profit rose 77.28% year-on-year. Hongte Technology plans to raise no more than 650 million yuan through a rights issue for its Thailand base and other projects. Tuoxin Pharmaceutical plans to raise no more than 228 million yuan through a private placement of shares. Biolight has terminated the planned change of control, and its shares and convertible bonds will resume trading on August 10. Huadong Medicine's wholly-owned subsidiary obtained EU MDR CE certification for its medical aesthetics product. Jumpcan Pharmaceutical's subsidiary obtained drug registration certificates for pediatric laxative granules and mesalazine sustained-release granules. Chinese Health's wholly-owned subsidiary had its drug registration application for ferrous succinate tablets accepted.

The A-share CRO sector surged on the morning of August 7, with the sector index climbing 7.37% to top all sector gainers. Among the 41 constituent stocks, 15 rose more than 10%, including Bide Pharmaceutical, Yaokang Bio, Baihua Pharmaceutical, Apeloa Pharmaceutical, and Asymchem hitting their daily limit up, while another 17 stocks such as BioMap, Joinn Laboratories, Tigermed, and WuXi AppTec gained over 5%. Earnings were the main driver, after BioMap released a profit forecast the previous evening, projecting attributable net profit of 236 million to 246 million yuan for the first half of 2026, a year-on-year increase of 3.92 to 4.13 times. So far, eight CRO companies have reported half-year results or profit forecasts, with six expecting double-digit or higher growth. Joinn Laboratories and Medicilon had previously forecast first-half profit to double. Sector leader WuXi AppTec reported in its half-year results this week that attributable net profit reached 11.08 billion yuan in the first half, up 29.43% year-on-year, surpassing 10 billion yuan for the first time in a first half. It also raised its full-year 2026 revenue guidance to between 58.5 billion and 60.5 billion yuan, with continuing operations revenue growth raised to 35% to 39%. The turnaround in CRO earnings stems from rising orders, as a sustained recovery in global pharmaceutical investment and financing drives renewed demand for innovative drug R&D. BioMap said its two major business lines achieved dual-engine growth, while WuXi AppTec's continuing operations backlog reached 66.43 billion yuan as of end-June, up 25.2% year-on-year. A research note from China Post Securities argued that overseas R&D outsourcing demand is steadily recovering, and a boost in domestic R&D outsourcing demand is expected to materialize in 2026.

WuXi AppTec has rarely sharply raised its full-year 2026 performance guidance, lifting overall revenue from the previous 51.3 billion to 53 billion yuan to 58.5 billion to 60.5 billion yuan, and raising the continuing operations revenue growth rate from 18 to 22 percent to 35 to 39 percent. Boosted by this, the company's A-shares hit the daily limit up, closing at 141.35 yuan, a new high since November 2021, with total market capitalization returning above 400 billion yuan. In the first half of the year, the company achieved operating revenue of 28.897 billion yuan, up 38.93 percent year-on-year, and net profit attributable to the parent of 11.08 billion yuan, up 29.43 percent year-on-year. The chemical business contributed the core increment, with revenue reaching 24.986 billion yuan, up 53.28 percent year-on-year, and small-molecule CDMO business revenue of 14.99 billion yuan, up 72.7 percent year-on-year. The company simultaneously launched an employee stock ownership plan for no more than 4,000 people, with performance assessment linked to 2026 operating revenue. The 100 percent vesting threshold is 53 billion yuan, below the lower end of the latest guidance. In the second quarter, northbound funds significantly increased their positions, with the Shanghai-Hong Kong Stock Connect adding 87.6823 million shares, and Hong Kong Securities Clearing Company Limited holding 261.6 million shares, firmly ranking as the largest tradable shareholder.

WuXi AppTec disclosed its 2026 semi-annual report, achieving operating revenue of 28.897 billion yuan, a year-on-year increase of 38.93 percent, and net profit attributable to the parent of 11.08 billion yuan, up 29.43 percent. It also raised its full-year overall revenue guidance from 51.3 billion to 53 billion yuan to 58.5 billion to 60.5 billion yuan. Daqin Railway plans to repurchase and cancel shares with its own funds of 400 million to 500 million yuan, at a repurchase price not exceeding 7.10 yuan per share. Torrance received a net institutional seat purchase of 103 million yuan. The company is a core domestic supplier of metal components for semiconductor equipment, with products compatible with advanced processes of 7 nanometers and below. The A-share market saw a contraction on August 3, with the STAR 50 Index falling 5.08 percent, but the micro-cap stock index rose 3.6 percent. The combined turnover of the Shanghai and Shenzhen markets was 1.9974 trillion yuan, with over 4,000 stocks advancing. The nuclear power sector strengthened on policy support, AI application themes remained active, the photovoltaic sector rebounded, while the memory chip segment came under pressure.

According to statistics from Securities Times Data Treasure, a total of 13 companies released their 2026 semi-annual reports on August 4. Among them, Jinyu Bio posted the largest profit increase, with net profit up 72.28 percent year-on-year. Jinyu Bio achieved net profit of 104 million yuan and operating revenue of 756 million yuan, up 22.09 percent. WuXi AppTec reported net profit of 11.08 billion yuan, up 29.43 percent, on operating revenue of 28.897 billion yuan, up 38.93 percent. Companies such as Jasan Group, Sinocare, Sihui Fushi, and Wanda Bearing also recorded net profit growth, while seven companies including Jiahuan Technology and Sinodata saw net profit decline year-on-year.

On August 4, major A-share indices opened collectively higher. The innovative drug concept continued to climb, with the CXO segment leading the gains. WuXi AppTec surged in a straight line to hit its daily limit-up, and Asymchem, Luoxin Pharmaceuticals, Jimin Health, and Harbin Medisan also hit limit-up. In terms of news, WuXi AppTec released its 2026 half-year report, with first-half revenue of 28.9 billion yuan, up 38.9 percent year-on-year, and attributable net profit exceeding 10 billion yuan for the first time in a first half, reaching 11.08 billion yuan, up 29.43 percent year-on-year. The company raised its full-year 2026 performance guidance across the board, lifting expected total revenue from a range of 51.3 billion to 53 billion yuan to a range of 58.5 billion to 60.5 billion yuan. The computing power leasing concept was repeatedly active, with QingCloud Technologies hitting the 20 percent limit-up and Meili Cloud achieving a three-day winning streak. Data from the China Academy of Information and Communications Technology showed that domestic AI computing power demand surged 417 percent year-on-year in the first quarter of 2026, while effective supply grew only 128 percent, widening the supply-demand gap. The nuclear power sector also strengthened, with LBT hitting a two-day winning streak. In terms of news, the National Development and Reform Commission and the National Energy Administration issued the 15th Five-Year Plan for New Power System Construction, proposing to promote large-scale nuclear power construction, with installed nuclear power capacity reaching approximately 110 million kilowatts by 2030.

WuXi AppTec has released its 2026 interim report, with net profit attributable to shareholders reaching 11.08 billion yuan. During the reporting period, total operating revenue was 28.897 billion yuan, and net cash inflow from operating activities was 9.699 billion yuan. The company's latest asset-liability ratio stands at 27.85 percent, up 6.77 percentage points from the previous quarter. Gross margin was 53.91 percent. Return on equity was 13.30 percent, down 0.99 percentage points from the same period last year. Diluted earnings per share were 3.80 yuan. Total asset turnover was 0.26 times, and inventory turnover was 1.32 times, a year-on-year decline of 28.09 percent. The company had 261,400 shareholders, with the top ten shareholders holding 42.62 percent of total share capital.

Multiple listed companies on the Shanghai and Shenzhen exchanges disclosed positive announcements on the evening of August 3. Sunshine Co.'s controlled subsidiary plans to invest up to 980 million yuan in building the Sunshine Intelligent Computing Center project. Xingyun Technology has long-term framework orders for computing power and storage on hand exceeding 15.4 billion yuan. Hainan Expressway's wholly-owned subsidiary plans to acquire a 100 percent stake in Jiaokong Technology for 36.1038 million yuan. Rongbai Technology's Guizhou base, with an annual production capacity of 340,000 tons of lithium iron phosphate, is expected to be fully operational by the end of September. Shengda Resources' controlled subsidiary's Caiyuanzi copper-gold mine has entered the formal production stage. Laier Technology plans to raise no more than 1.17 billion yuan through a private placement for new energy carbon-coated foil and other projects. China Micro Corporation expects its first-half net profit to grow by 282.48 percent to 310.81 percent year-on-year. WuXi AppTec's first-half net profit rose 29.43 percent year-on-year, and it plans to distribute 5.1 yuan per 10 shares. Shandong Hi-Speed plans to repurchase shares worth 100 million to 200 million yuan for cancellation. Wuliangye has already spent 1.002 billion yuan on share repurchases. Daqin Railway plans to repurchase shares worth 400 million to 500 million yuan for cancellation. Sinoma International signed a 476 million US dollar equipment supply contract with a company under the Dangote Group. Gaole Co.'s wholly-owned subsidiary signed a 3.195 billion yuan computing power service contract. Nanfang Precision plans to bid for land and invest about 1.024 billion yuan in building a precision components project. Sungrow Power plans to repurchase shares worth 500 million to 1 billion yuan. Shida Shenghua plans to invest a total of 2.805 billion yuan in building three projects for liquid lithium salt, electrolyte, and others.

WuXi AppTec has released a draft of its 2026 A-share employee stock ownership plan, proposing to grant up to 9.7012 million company A-shares to no more than 4,000 managerial staff and core technical personnel. The purchase price is 103.08 yuan per share, funded by the company's long-term incentive fund, with a total amount not exceeding 1 billion yuan. The plan has a duration of 60 months and will be unlocked in four phases, each unlocking 25 percent. The performance assessment target is that if 2026 revenue reaches 53 billion yuan or above, 100 percent of the shares will vest. If 2026 revenue reaches 51.3 billion yuan or above but falls short of 53 billion yuan, 60 percent of the target shares will vest. If 2026 revenue falls short of 51.3 billion yuan, no target shares will vest.

On the evening of August 3, several listed companies disclosed important announcements. Daqin Railway plans to repurchase shares at a price not exceeding 7.10 yuan per share, spending between 400 million and 500 million yuan to buy back and cancel all repurchased shares, thereby reducing registered capital. The controlling shareholder of Soochow Securities, Guofa Group, plans to increase its holdings of company shares by 100 million to 200 million yuan within six months. Both Bethel Automotive and Shenglan Technology plan to repurchase shares worth 100 million to 200 million yuan, to be used for employee stock ownership plans or equity incentives, and for equity incentives or convertible bond conversions, respectively. WuXi AppTec disclosed its half-year report, achieving operating revenue of 28.897 billion yuan in the first half of 2026, a year-on-year increase of 38.93%, with net profit attributable to shareholders of the listed company reaching 11.08 billion yuan, up 29.43% year-on-year, and plans to distribute a cash dividend of 5.10 yuan for every 10 shares. Advanced Micro-Fabrication Equipment expects a net profit attributable to the parent company of between 2.7 billion and 2.9 billion yuan for the first half of the year, a year-on-year increase of 282% to 310%, mainly due to revenue growth and a total of approximately 1.982 billion yuan in fair value changes and investment income from external equity investments. A subsidiary of Shida Shenghua's wholly-owned unit plans to invest in the construction of a 230,000-ton-per-year liquid lithium salt project, with an estimated total investment of 1.9 billion yuan and a reported investment of 1.7973723 billion yuan; another wholly-owned subsidiary plans to invest in a 200,000-ton-per-year electrolyte project, with an estimated total investment of 721.5 million yuan; additionally, the wholly-owned subsidiary Dongying Company plans to invest in a 12,000-ton-per-year additive project, with an estimated reported total investment of 285.87 million yuan. The wholly-owned subsidiary of Goldlok Holdings, Zhichen Technology, signed a computing power service contract worth 3.195 billion yuan, with a service term of five years, expected to add approximately 200 million yuan in revenue for the company in 2026. Both Dali Technology and Renzi Xing received approval from the exchange to remove their risk warnings, will suspend trading for one day on August 4, and resume trading on August 5 with changed stock abbreviations.

The revised Regulations on the Protection of Layout-Designs of Integrated Circuits have been officially published and will take effect on October 15, 2026. This marks the first comprehensive revision since the regulations were implemented in 2001. Industry insiders believe the revised regulations serve as a key institutional cornerstone for China's integrated circuit industry to transition from scale expansion to high-quality development. They are expected to help establish a positive cycle of innovation, protection, revenue, and re-innovation, and assist China's integrated circuit industry in gradually shifting from a follower to a rule maker and original leader in global competition. In other news, Galactic Energy announced it will soon carry out the first commercial launch mission of its Ceres-1 rocket at an opportune time. The medium-to-large reusable liquid-propellant launch vehicle, independently developed by the company, is about to undergo its maiden flight verification, with a design allowing up to 25 reuses. An international standard led by China, titled Blockchain and Distributed Ledger Technologies – Technical Framework and Functional Requirements for Blockchain as a Service, has recently been approved as a project by the International Organization for Standardization. Countries including Germany, the United Kingdom, and Japan will send representatives to participate in its development. On the corporate front, WuXi AppTec has comprehensively raised its 2026 performance guidance, with overall revenue expected to increase from a range of 51.3 to 53 billion yuan to a range of 58.5 to 60.5 billion yuan. Advanced Micro-Fabrication Equipment expects its net profit for the first half of the year to grow by 282 to 311 percent year-on-year.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

The Hang Seng Index climbed 340.37 points, or 1.4%, to 24,681.10 on the Hong Kong market on the 15th, marking a fourth consecutive advance. Easing expectations for US rate hikes provided support, as the probability of a rate increase at this month's FOMC meeting plunged to around 10% following slower growth in the June US consumer price index, also alleviating concerns over rising domestic interest rates in Hong Kong. However, gains were capped after China's April-to-June GDP growth came in at 4.3% during trading hours, missing the forecast of 4.5% and decelerating from 5.0% in the previous quarter. Among Hang Seng Index constituents, pharmaceutical stocks rose, with Innovent Biologics up 7.8% and WuXi AppTec up 4.4%, while Hong Kong property and AI-related shares also attracted buying. On the other hand, resource stocks fell, with Lingbao Gold Group down 5.5% and Chifeng Jilong Gold Mining down 5.1%.

Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply. Targeted protein degraders, covalent agents, and a new wave of kinase inhibitors move through pipelines that classical workflows were not built to support. WuXi AppTec, a contract research, development, and manufacturing organization, works as a trusted partner to the biotech and pharmaceutical innovators developing these medicines. When discovery, development, and manufacturing are connected under one partner, decisions made early carry forward, compressing timelines without sacrificing continuity.

The Hong Kong stock market is expected to open lower on Monday, extending a three-session losing streak that has wiped out more than 900 points or 3.8 percent from the Hang Seng Index, which now sits just above the 23,920-point plateau. The Hang Seng tumbled 387.35 points or 1.59 percent to finish at 23,924.81 on Thursday, with financial shares, property stocks, and technology companies ending mostly in the red. Among major movers, China Life Insurance cratered 6.60 percent, Lenovo Group plummeted 4.42 percent, Ping An Insurance plunged 4.01 percent, and WuXi AppTec surged 5.06 percent. The negative lead comes after European markets ended mostly underwater on Friday, with the UK's FTSE 100 down 0.35 percent, Germany's DAX drifting down 0.16 percent, and France's CAC 40 losing 0.55 percent, while U.S. markets were closed for the Juneteenth holiday. Weakness was driven by renewed geopolitical uncertainty after Iran closed the Strait of Hormuz again over the weekend, following the abrupt cancellation of peace talks between the U.S. and Iran in Switzerland, which is likely to prompt a rebound in crude oil prices this week.

The global cell and gene therapy CDMO market is projected to grow from $8.3 billion in 2025 to $57.1 billion by 2034, at a compound annual growth rate of approximately 24%, according to a report by DelveInsight. North America held the largest share in 2025, accounting for roughly 40% of the global market, driven by an expanding pipeline of cell and gene therapies and substantial investments in innovative technologies. Key companies in the market include Catalent, Minaris Advanced Therapies, SCTbio, Cellex Cell Professionals, Mycenax Biotech, MedTherapy Biotech, ENCELL, Nucelion Biotechnologies, Charles River Laboratories, Lonza Group, Thermo Fisher Scientific, and WuXi AppTec. Recent developments include Catalent expanding its agreement with Cartherics for iPSC-derived CAR-NK cell therapies in April 2026, and Lonza expanding its manufacturing agreement with Genetix Biotherapeutics for ZYNTEGLO in March 2026. The market growth is fueled by rising numbers of cell and gene therapy candidates, increasing outsourcing trends, and advancements in manufacturing technologies.